Oppenheimer & Co. Inc. Cuts Holdings in HCA Healthcare, Inc. $HCA

Oppenheimer & Co. Inc. lessened its stake in HCA Healthcare, Inc. (NYSE:HCA) by 10.0% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 11,082 shares of the company’s stock after selling 1,230 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in HCA Healthcare were worth $5,174,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Holos Integrated Wealth LLC purchased a new position in HCA Healthcare in the 4th quarter worth approximately $29,000. Palisade Asset Management LLC purchased a new position in HCA Healthcare in the 3rd quarter worth approximately $26,000. Ares Financial Consulting LLC bought a new position in shares of HCA Healthcare during the 4th quarter valued at $31,000. Aventura Private Wealth LLC bought a new position in shares of HCA Healthcare during the 4th quarter valued at $34,000. Finally, Key Capital Management INC bought a new position in shares of HCA Healthcare during the 4th quarter valued at $35,000. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Trading Down 0.2%

NYSE:HCA opened at $433.73 on Friday. The company has a 50-day moving average price of $497.66 and a 200-day moving average price of $485.93. HCA Healthcare, Inc. has a 12 month low of $330.00 and a 12 month high of $556.52. The stock has a market cap of $96.50 billion, a price-to-earnings ratio of 14.92, a P/E/G ratio of 1.37 and a beta of 1.19.

HCA Healthcare (NYSE:HCA) last posted its earnings results on Friday, April 24th. The company reported $7.15 EPS for the quarter, missing the consensus estimate of $7.19 by ($0.04). HCA Healthcare had a negative return on equity of 295.93% and a net margin of 8.89%.The company had revenue of $19.11 billion during the quarter, compared to analysts’ expectations of $19.09 billion. During the same period in the prior year, the business posted $6.45 earnings per share. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. Equities analysts forecast that HCA Healthcare, Inc. will post 30.05 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 16th will be given a $0.78 dividend. This represents a $3.12 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Tuesday, June 16th. HCA Healthcare’s dividend payout ratio (DPR) is currently 10.73%.

Analyst Ratings Changes

Several research firms recently commented on HCA. Argus increased their target price on shares of HCA Healthcare from $530.00 to $560.00 and gave the company a “buy” rating in a report on Friday, February 6th. Leerink Partners reduced their target price on shares of HCA Healthcare from $573.00 to $500.00 and set an “outperform” rating on the stock in a report on Monday, April 27th. Jefferies Financial Group reaffirmed a “buy” rating and set a $525.00 target price on shares of HCA Healthcare in a report on Friday, April 24th. Oppenheimer dropped their price target on shares of HCA Healthcare from $540.00 to $520.00 and set an “outperform” rating for the company in a research report on Monday, April 27th. Finally, Truist Financial dropped their price target on shares of HCA Healthcare from $546.00 to $535.00 and set a “buy” rating for the company in a research report on Monday, April 27th. Sixteen research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, HCA Healthcare presently has an average rating of “Moderate Buy” and a consensus price target of $520.55.

Insider Activity at HCA Healthcare

In other news, SVP Christopher F. Wyatt sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $505.00, for a total value of $2,020,000.00. Following the completion of the sale, the senior vice president directly owned 44,379 shares of the company’s stock, valued at approximately $22,411,395. This trade represents a 8.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Michael S. Cuffe sold 1,500 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $498.09, for a total transaction of $747,135.00. Following the completion of the transaction, the executive vice president owned 30,003 shares of the company’s stock, valued at approximately $14,944,194.27. The trade was a 4.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 15,214 shares of company stock valued at $7,797,595. 1.50% of the stock is currently owned by company insiders.

HCA Healthcare Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.